CD274 and non-small cell lung carcinoma: In a recent phase II study, Nadal et al. evaluated the combination of atezolizumab (an anti-PDL-1 immune checkpoint inhibitor) with carboplatin and pemetrexed in patients with NSCLC with a stable, untreated BM lesion.